---
title: "GLP-1s and Their Role in Menopause Care"
description: "Weight gain during perimenopause and menopause is often tied to hormonal shifts that affect appetite, sleep, muscle mass, insulin sensitivity, and fat distribution. GLP-1 medications such as semaglutide and tirzepatide can support weight loss and metabolic health, but the best choice depends on a woman’s symptoms, health history, treatment goals, and tolerance for side effects. Midlife women may also need to think about muscle preservation, cardiovascular risk, and whether menopausal hormone therapy could complement weight treatment."
url: "https://www.myalloy.com/blog/glp-1-weight-loss-drug-comparison-guide"
---

# GLP-1s and Their Role in Menopause Care

*How midlife changes can shape the benefits, tradeoffs, and treatment decisions around GLP-1 medications*

By Alloy Health Editorial Team

## Summary

**GLP-1 medications** can support weight management for eligible women during **perimenopause and menopause**, but they do not treat hormonal menopause symptoms. Semaglutide, tirzepatide, and liraglutide differ in effectiveness, dosing, indications, and side effects, while nutrition and resistance exercise can help preserve muscle during treatment; medical history, contraception, other medications, and hormone therapy should also be considered when choosing treatment.

[Start Your Weight Care Consult](https://secure.myalloy.com/experience?categories%5B%5D=weight-health&sku-ids%5B%5D=6f32bad4-76bd-4b07-8bbd-233c298bb222%2C32f106c4-4054-4f19-a774-dfe9afc12190&skip-category-select=true&type=intake)

## GLP-1s and Their Role in Menopause Care

If the strategies that kept your weight steady for years have stopped working, midlife may be part of the reason. Changes in body composition, sleep, and energy can make your body feel different.

You’ve probably also heard a lot about GLP-1 medications like [semaglutide](https://www.myalloy.com/solutions/compounded-semaglutide) and [tirzepatide](https://www.myalloy.com/solutions/compounded-tirzepatide), and wondered whether one could help you. Possibly. GLP-1s don’t treat menopause or its hormonal symptoms, but for some women, they can be an appropriate option for weight loss. Here’s why weight can change during menopause, what GLP-1s actually treat, and how the options compare, so you can have a more informed conversation with your doctor. 

## Why Weight Changes in Menopause Can Feel Different

One of the changes you might notice during perimenopause and menopause is that your body starts carrying weight differently, often more around your midsection than your hips or thighs. Changes in insulin sensitivity associated with fluctuating hormone levels, along with age-related muscle loss, can make maintaining your weight and metabolic health even more challenging.

In addition, the presence of hot flashes, disrupted sleep, mood changes, and other common menopause symptoms can also indirectly make managing weight harder by affecting energy, eating patterns, and physical activity.

When all these factors overlap, it can help explain why midlife weight changes aren't always simply a reflection of diet, exercise, or willpower.

###  

## How GLP-1 Medications Work in the Body

GLP-1 is a naturally occurring hormone involved in appetite, satiety, glucose regulation, and digestion. GLP-1 medications act on this pathway to slow gastric emptying and reduce hunger, helping people feel full sooner and for longer. GLP-1 receptor agonists, along with the dual GIP/GLP-1 receptor agonist tirzepatide, are among the most effective medications currently available for weight management.

“Menopause can sometimes feel like your metabolism suddenly changed the rules! As we age, our metabolism naturally slows, and the muscle loss that can occur during midlife and menopause can make it even harder to burn calories like we used to. Suddenly, the strategies that worked in our 30s may not work quite as well. GLP-1 medications can be a helpful tool during this transition by reducing appetite, increasing fullness, and making weight loss more achievable. For many women, they can provide a much-needed springboard—not just to lose weight, but to build sustainable habits and help stabilize weight while navigating the many changes of menopause.” –Kathryn Williams, MD, MSCP, DABOM

###  

## Where GLP-1 Medications Fit into Menopause Care

GLP-1 medications aren't treatments for menopause itself. They are approved to treat specific medical conditions, including type 2 diabetes and, for certain formulations, chronic weight management. Some also have additional indications related to cardiovascular or kidney disease.

Some women entering perimenopause and menopause may already be living with obesity, diabetes, cardiovascular disease, or other health conditions for which these medications may be appropriate. The menopause transition can also bring changes in body composition and factors that affect heart and metabolic health, making it a good time to think about your long-term health. 

For women with established indications, GLP-1 and related medications can have benefits that go beyond the numbers on their scale. For women without preexisting metabolic disease who are primarily experiencing midlife weight changes, the picture is less clear. Research specifically examining GLP-1 use during perimenopause and menopause is growing, but we don't yet know whether the menopause transition itself should influence when these medications are used or which one is selected.

What we do know is that women who meet established treatment criteria have several options, and those options aren't identical.

###  

## Semaglutide, Tirzepatide, and Liraglutide

Here’s how the three most common options compare for weight management. If you have diabetes, heart disease, or another condition that could affect treatment, talk with your doctor before considering therapy with a GLP-1 or beginning any other weight-management medication or protocol.

There isn't one GLP-1 medication that's best for every woman.

**Tirzepatide **[**(Zepbound)**](https://www.myalloy.com/solutions/zepbound-kwikpen) is a once-weekly injection and produces greater average weight loss than semaglutide in direct clinical comparisons, because it acts on two hormone pathways, GIP and GLP-1.

**Compounded Tirzepatide**

Plus $99/month Alloy Weight Care

Weekly injection. Personalized dosing for gentler starts and individual goals**


[Start Now](https://secure.myalloy.com/experience?categories%5B%5D=weight-health&sku-ids%5B%5D=6f32bad4-76bd-4b07-8bbd-233c298bb222%2C32f106c4-4054-4f19-a774-dfe9afc12190%2C232781d7-0c96-4e95-a1ae-adfd51bb8cc5&skip-category-select=true&skip-treatment-select=true&type=intake)

**Semaglutide **[**(Wegovy)**](https://www.myalloy.com/solutions/wegovy-pill) is available as a once-weekly injection and a daily tablet. It is also approved to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and overweight or obesity, which may be an important consideration for some women.

[**Liraglutide**](https://www.myalloy.com/solutions/compounded-liraglutide)** (Saxenda)** is a once-daily injection. It generally produces less average weight loss than tirzepatide or semaglutide but remains an established option for chronic weight management.

**Compounded Liraglutide**


Plus $99/month Alloy Weight Care

Daily injection. Personalized dosing for gentler starts and individual goals.**


[Start Now](https://secure.myalloy.com/experience?categories%5B%5D=weight-health&sku-ids%5B%5D=6f32bad4-76bd-4b07-8bbd-233c298bb222%2C32f106c4-4054-4f19-a774-dfe9afc12190%2C56bc1cf8-b7f9-4ed9-938c-82f4a742bc1f&skip-category-select=true&skip-treatment-select=true&type=intake)

Although tirzepatide is associated with the greatest average weight loss, it may not be the best choice for every woman. Cost, administration, side effects, health history, and personal preferences may all influence which option is the best fit.

###  

## Side Effects to Consider when Using GLP-1 Medications in Midlife

Gastrointestinal side effects such as nausea, constipation, diarrhea, vomiting, indigestion, and reflux are common with these medications, and so is reduced appetite. Reduced appetite can make it easier to eat less than intended, including less protein and other nutrients that are needed to support muscle and overall health during midlife. Preserving lean mass is especially relevant during perimenopause and menopause because of age-related muscle loss that occurs during this time.

Getting enough protein and incorporating resistance exercises, such as lifting weights, can help maintain muscle mass during treatment with a GLP-1. If reduced appetite makes it difficult to meet your nutritional needs, a registered dietitian can help you find ways to get adequate nutrition even when you're eating less. 

Side effects occur most often with dose increases and dose-escalation schedules are designed to make it easier to tolerate increases. If side effects are persistent or if they are interfering with eating, it's important to talk with your prescribing clinician rather than trying to push through them. 

###  

## GLP-1 Medications and HRT

If you're already familiar with hormone therapy and are curious about GLP-1 medications, you might wonder whether the two treatments affect each other.

Some [early research](https://doi.org/10.1016/S3050-5038(25)00145-1?utm) suggests there may be a connection for midlife women. [Studies](https://pmc.ncbi.nlm.nih.gov/articles/PMC11209769/?utm) have found that women using both treatments sometimes experienced greater weight loss than those taking GLP-1 medications without hormone therapy. However, these findings haven't been consistent across medications, and more research is needed to understand the relationship between these treatments.

Hormone therapy isn't a weight-loss treatment, but it can effectively relieve some of the most bothersome symptoms of menopause, including hot flashes and night sweats. HRT and GLP-1 medications each have their own purpose, and decisions about using either should be based on your symptoms, medical history, and individual health needs.

[Watch video](https://www.youtube.com/watch?v=PVFjrKs1Kog)

## Who Should Be More Cautious

Each medication’s FDA label includes contraindications, warnings, and precautions which vary by drug. They may involve pregnancy, certain thyroid cancer histories, gastrointestinal conditions, pancreatitis, and gallbladder disease.

Because these medications slow how quickly your stomach empties, your doctor may also need to consider how they interact with other medications you take by mouth.

That includes birth control pills. If you’re in perimenopause and take an oral hormonal contraceptive, tirzepatide specifically may make it less effective, especially when you first start and each time your dose goes up, which is when its effect on stomach emptying is strongest. Ask your doctor what starting tirzepatide means for your contraception.

###  

## Questions to Ask Before Starting a GLP-1

Before starting treatment, talk with your clinician about your weight-management goals, health history, other medications, preferred route and dosing schedule, and potential side effects. It can also help to discuss how treatment response will be monitored and what the plan will be if you experience persistent side effects, reach a plateau, or eventually want to stop or switch medications.

If menopause symptoms are also affecting your health or quality of life, talk with your doctor about those specifically. A GLP-1 will not treat the hormonal symptoms of menopause, but other therapies can help. A clinician experienced in menopause care can help you understand your options and how they may fit together.

Alloy Health connects you with a board-certified, menopause-specialized doctor who can look at weight management and your other menopause symptoms together, with your health history and current treatments in mind.

[Start Now](https://secure.myalloy.com/experience?categories%5B%5D=weight-health&sku-ids%5B%5D=6f32bad4-76bd-4b07-8bbd-233c298bb222%2C32f106c4-4054-4f19-a774-dfe9afc12190&skip-category-select=true&type=intake)

---

## Frequently Asked Questions



### Do GLP-1 medications treat menopause symptoms, and how do the main options compare?

GLP-1 medications do not treat menopause or its hormonal symptoms directly, though they can be an effective option for chronic weight management during midlife. These medications work by slowing gastric emptying, reducing hunger, and helping you feel full sooner and for longer. Among the three most common options, [tirzepatide (Zepbound)](https://www.myalloy.com/solutions/zepbound) is a once-weekly injection targeting both GIP and GLP-1 pathways that produces the greatest average weight loss. [Semaglutide (Wegovy)](https://www.myalloy.com/solutions/wegovy), available as a once-weekly injection or daily tablet, is also approved to reduce the risk of heart attack, stroke, and cardiovascular death in adults with established cardiovascular disease and overweight or obesity. Liraglutide (Saxenda) is a once-daily injection that generally produces less average weight loss than tirzepatide or semaglutide.

### Can you take GLP-1 medications alongside hormone replacement therapy (HRT), and how do you protect muscle mass?

While hormone replacement therapy (HRT) is used to relieve menopause symptoms like hot flashes and night sweats rather than to promote weight loss, some early research suggests that women taking both HRT and GLP-1 medications sometimes experience greater weight loss than those using GLP-1s alone. However, these findings have not been consistent across all medications, and more research is needed. Additionally, because GLP-1s reduce appetite and can cause gastrointestinal side effects, it is essential to eat enough protein and incorporate resistance exercises like lifting weights to protect lean mass against age-related midlife muscle loss.

### Who should exercise caution with GLP-1 medications, and do they affect birth control pills?

Each GLP-1 medication carries FDA contraindications, warnings, and precautions that vary by drug, involving factors such as pregnancy, certain thyroid cancer histories, pancreatitis, gallbladder disease, and gastrointestinal conditions. Furthermore, because these drugs slow how quickly the stomach empties, they can affect how your body absorbs oral medications. Specifically, if you are in perimenopause and take oral hormonal contraceptives, tirzepatide may make birth control pills less effective when you first start treatment and each time your dose increases.

## 


---

## References

1. Greendale GA, Sternfeld B, Huang MH, et al. Changes in body composition and weight during the menopause transition. *JCI Insight.* 2019;4(5):e124865. doi:10.1172/jci.insight.124865
2. Aronne LJ, Horn DB, le Roux CW, et al; SURMOUNT-5 Trial Investigators. Tirzepatide as compared with semaglutide for the treatment of obesity. *N Engl J Med.* 2025;393(1):26-36. doi:10.1056/NEJMoa2416394
3. Tchang BG, Ciudin Mihai A, Stefanski A, et al. Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. *Obesity (Silver Spring).* 2025;33(5):851-860. doi:10.1002/oby.24254
4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med.* 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563
5. Hurtado MD, Tama E, Fansa S, et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. *Menopause*. 2024;31(4):266-274. doi:10.1097/GME.0000000000002310 
6. Castaneda R, Bechenati D, Tama E et al. The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study. *The Lancet Obstetrics, Gynaecology, & Women’s Health*, 2026; 2(2):e118-e128. doi:org/10.1016/S3050-5038(25)00145-1?utm
7. US Food and Drug Administration. *Wegovy (semaglutide) prescribing information.* Updated 2026. Accessed August 30, 2026.
8. US Food and Drug Administration. *Zepbound (tirzepatide) prescribing information.* Updated 2026. Accessed August 30, 2026.
9. US Food and Drug Administration. *Saxenda (liraglutide) prescribing information.* Updated 2025. Accessed August 30, 2026.

## Related Content

1. [https://www.myalloy.com/blog/how-do-glp-1s-work](https://www.myalloy.com/blog/how-do-glp-1s-work)
2. [https://www.myalloy.com/blog/midlife-weight-gain-why-is-it-so-hard-to-lose](https://www.myalloy.com/blog/midlife-weight-gain-why-is-it-so-hard-to-lose)
3. [https://www.myalloy.com/solutions](https://www.myalloy.com/solutions)
4. [https://www.myalloy.com/blog/are-glp-1-medications-safe-and-what-about-side-effects](https://www.myalloy.com/blog/are-glp-1-medications-safe-and-what-about-side-effects)
5. [https://www.myalloy.com/blog/why-glp-1s-and-mht-are-a-beneficial-combination](https://www.myalloy.com/blog/why-glp-1s-and-mht-are-a-beneficial-combination)
6. [https://myalloy.zendesk.com/hc/en-us/articles/39471023349523-Can-I-take-GLP-1-medication-with-Menopausal-Hormone-Therapy-MHT](https://myalloy.zendesk.com/hc/en-us/articles/39471023349523-Can-I-take-GLP-1-medication-with-Menopausal-Hormone-Therapy-MHT)
7. [https://www.myalloy.com/providers](https://www.myalloy.com/providers)
8. [https://www.myalloy.com/solutions/wegovy](https://www.myalloy.com/solutions/wegovy)
9. [https://www.myalloy.com/blog/are-your-menopause-symptoms-worse-than-expected](https://www.myalloy.com/blog/are-your-menopause-symptoms-worse-than-expected)
10. [https://www.youtube.com/watch?v=PQ60VjfnliA](https://www.youtube.com/watch?v=PQ60VjfnliA)
11. [https://www.youtube.com/watch?v=O7vLhOakPdY](https://www.youtube.com/watch?v=O7vLhOakPdY)

## Citations

1. Hana Mikdachi, Rebecca Dunsmoor-Su. GLP-1 receptor agonists for weight loss for perimenopausal and postmenopausal women: current evidence. Curr Opin Obstet Gynecol 2025;37(2):97-101. PMID:39970049. — [View source](https://www.ovid.com/10.1097/GCO.0000000000001015)
2. Tchang BG, Ciudin Mihai A, Stefanski A, et al. Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity (Silver Spring). 2025;33(5):851-860. PMID:40074721. — [View source](https://pmc.ncbi.nlm.nih.gov/articles/pmid/40074721/)
3. Maria D Hurtado, Elif Tama, Sima Fansa, Wissam Ghusn, Diego Anazco, Andres Acosta, et al.. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause 2024;31(4):266-274. PMID:38446869. — [View source](https://pmc.ncbi.nlm.nih.gov/articles/pmid/38446869/)
4. Joana Nicolau, Jorge Blanco-Anesto, Aina Bonet, Juan José Félix-Jaume, Apolonia Gil-Palmer. Effectiveness of Low Doses of Semaglutide on Weight Loss and Body Composition Among Women in Their Menopause. Metab Syndr Relat Disord 2025;23(1):70-76. PMID:39761057. — [View source](https://pubmed.ncbi.nlm.nih.gov/39761057/)
5. Santiago Palacios, Peter Chedraui, Rafael Sanchez-Borrego, Pluvio Coronado, Tommaso Simoncini, Katrin Schauding, et al.. Management of obesity in menopause. Climacteric 2024;27(4):357-363. PMID:39016333. — [View source](https://www.tandfonline.com/doi/10.1080/13697137.2024.2374760?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed)
6. Courtney Younglove. Clinical review: Menopause hormone therapy in weight management. Obes Pillars 2026;18:100258. PMID:41883510. — [View source](https://linkinghub.elsevier.com/retrieve/pii/S2667-3681%2826%2900014-8)
7. Zhang W, Wu Q, Chen Q, et al. Adipose-muscle crosstalk during the menopausal transition: mechanistic links to sarcopenic obesity in midlife women. Front Endocrinol (Lausanne). 2026;17:1805067. PMID:42158910. — [View source](https://pmc.ncbi.nlm.nih.gov/articles/pmid/42158910/)
8. Annice Mukherjee, Sadaf Ghaem-Maghami, Akheel A Syed. Use of incretin-based therapies in women using hormone replacement therapy (HRT). Post Reprod Health 2025;31(2):127-131. PMID:40378270. — [View source](https://www.tandfonline.com/doi/10.1177/20533691251343069?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed)

---

*This is a markdown version of [https://www.myalloy.com/blog/glp-1-weight-loss-drug-comparison-guide](https://www.myalloy.com/blog/glp-1-weight-loss-drug-comparison-guide) for AI/LLM consumption.*